UiPath (NYSE:PATH) Price Target Lowered to $14.00 at Wells Fargo & Company

UiPath (NYSE:PATH) had its target price reduced by equities research analysts at Wells Fargo & Company from $15.00 to $14.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the healthcare company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 23.08% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. TD Cowen reissued a “hold” rating and issued a $17.00 price objective (down from $28.00) on shares of UiPath in a research note on Thursday, May 30th. Mizuho decreased their price objective on shares of UiPath from $25.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, May 30th. William Blair cut shares of UiPath from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 30th. Macquarie cut shares of UiPath from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $29.00 to $12.00 in a research note on Monday, June 3rd. Finally, BMO Capital Markets decreased their price objective on shares of UiPath from $28.00 to $14.00 and set a “market perform” rating on the stock in a research note on Monday, June 3rd. Sixteen investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, UiPath currently has a consensus rating of “Hold” and an average price target of $18.06.

UiPath Trading Up 1.0 %

Shares of PATH opened at $11.38 on Friday. UiPath has a 12 month low of $11.07 and a 12 month high of $27.87. The firm’s 50 day moving average is $17.24 and its 200-day moving average is $21.38. The stock has a market capitalization of $6.52 billion, a PE ratio of -71.09 and a beta of 0.85.

Insider Activity at UiPath

In other UiPath news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $21.66, for a total value of $866,400.00. Following the completion of the sale, the chief financial officer now directly owns 660,762 shares of the company’s stock, valued at $14,312,104.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 22.37% of the stock is owned by company insiders.

Institutional Investors Weigh In On UiPath

Several hedge funds and other institutional investors have recently bought and sold shares of PATH. Mark Sheptoff Financial Planning LLC bought a new stake in UiPath in the fourth quarter valued at $25,000. HighMark Wealth Management LLC bought a new stake in UiPath in the fourth quarter valued at $27,000. ORG Partners LLC increased its stake in UiPath by 875.6% in the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock valued at $27,000 after purchasing an additional 1,112 shares in the last quarter. Cypress Capital Management LLC WY bought a new stake in UiPath in the fourth quarter valued at $29,000. Finally, GAMMA Investing LLC bought a new stake in UiPath in the fourth quarter valued at $36,000. 62.50% of the stock is owned by institutional investors.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.